ES2668300T3 - Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos - Google Patents

Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos Download PDF

Info

Publication number
ES2668300T3
ES2668300T3 ES13784562.4T ES13784562T ES2668300T3 ES 2668300 T3 ES2668300 T3 ES 2668300T3 ES 13784562 T ES13784562 T ES 13784562T ES 2668300 T3 ES2668300 T3 ES 2668300T3
Authority
ES
Spain
Prior art keywords
compound
alkyl
pharmaceutically acceptable
disease
fluoroalyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13784562.4T
Other languages
English (en)
Spanish (es)
Inventor
Mandar Deodhar
Alison Dorothy FINDLAY
Jonathan Stuart Foot
Wolfgang JAROLIMEK
Ian Alexander Mcdonald
Alan Robertson
Craig Ivan Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2668300T3 publication Critical patent/ES2668300T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/26—Thiols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES13784562.4T 2012-05-02 2013-04-05 Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos Active ES2668300T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641814P 2012-05-02 2012-05-02
US201261641814P 2012-05-02
PCT/AU2013/000356 WO2013163675A1 (en) 2012-05-02 2013-04-05 Substituted 3-haloallylamine inhibitors of ssao and uses thereof

Publications (1)

Publication Number Publication Date
ES2668300T3 true ES2668300T3 (es) 2018-05-17

Family

ID=49514094

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13784562.4T Active ES2668300T3 (es) 2012-05-02 2013-04-05 Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos

Country Status (24)

Country Link
US (4) US9302986B2 (cg-RX-API-DMAC7.html)
EP (2) EP3438087A1 (cg-RX-API-DMAC7.html)
JP (3) JP6182595B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200030126A (cg-RX-API-DMAC7.html)
CN (2) CN107266332B (cg-RX-API-DMAC7.html)
AU (2) AU2013255103B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014027406B1 (cg-RX-API-DMAC7.html)
CA (2) CA2871793C (cg-RX-API-DMAC7.html)
CY (1) CY1120334T1 (cg-RX-API-DMAC7.html)
DK (1) DK2844637T5 (cg-RX-API-DMAC7.html)
ES (1) ES2668300T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180953T1 (cg-RX-API-DMAC7.html)
HU (1) HUE038437T2 (cg-RX-API-DMAC7.html)
LT (1) LT2844637T (cg-RX-API-DMAC7.html)
ME (1) ME03063B (cg-RX-API-DMAC7.html)
MX (2) MX377635B (cg-RX-API-DMAC7.html)
NO (1) NO2842608T3 (cg-RX-API-DMAC7.html)
PL (1) PL2844637T3 (cg-RX-API-DMAC7.html)
PT (1) PT2844637T (cg-RX-API-DMAC7.html)
RS (1) RS57086B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201707020TA (cg-RX-API-DMAC7.html)
SI (1) SI2844637T1 (cg-RX-API-DMAC7.html)
TR (1) TR201807453T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013163675A1 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377635B (es) * 2012-05-02 2025-03-11 Boehringer Ingelheim Int Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
JP2018076236A (ja) * 2015-06-05 2018-05-17 株式会社アールテック・ウエノ がんを処置するための医薬組成物
AU2016366635A1 (en) 2015-12-07 2018-06-21 Benevolentai Cambridge Limited VAP-1 inhibitors for treating pain
SG11201806700RA (en) * 2016-02-12 2018-09-27 Pharmaxis Ltd Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
WO2018027892A1 (en) * 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
MX2019004549A (es) * 2016-10-19 2019-06-12 Boehringer Ingelheim Int Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
CN108341752B (zh) * 2017-01-21 2022-12-23 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
JP7145872B2 (ja) 2017-03-01 2022-10-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング α－ハロ－アクリル酸誘導体の遷移金属触媒によるプロト脱炭酸
US20200069648A1 (en) * 2017-03-02 2020-03-05 Pharmaxis Ltd. Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
US20200087248A1 (en) * 2017-04-28 2020-03-19 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fluoroallylamine Derivative And Use Thereof
CN110662534A (zh) 2017-05-31 2020-01-07 勃林格殷格翰国际有限公司 包含(e)-4-(2-(氨基甲基)-3-氟烯丙基氧基)-n-叔丁基苯甲酰胺的药物组合物和药物剂型，其制备方法、治疗方法及用途
GB201709136D0 (en) * 2017-06-08 2017-07-26 Proximagen Ltd New therapeutic uses of enzyme inhibitors
CN110719902B (zh) * 2017-06-20 2022-08-12 山东丹红制药有限公司 Ssao抑制剂
CN109251166B (zh) * 2017-07-13 2021-11-05 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
WO2019024924A1 (zh) * 2017-08-04 2019-02-07 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN109810041B (zh) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988109B (zh) * 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
CN109988106B (zh) * 2017-12-29 2023-03-31 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
AU2019238090B2 (en) 2018-03-22 2024-08-01 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US20210238192A1 (en) * 2018-06-29 2021-08-05 Blade Therapeutics, Inc. Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof
KR20200004036A (ko) * 2018-07-03 2020-01-13 주식회사유한양행 (e)-(2-(클로로메틸)-3-플루오로알릴)카바메이트 유도체의 제조방법
CA3105599A1 (en) 2018-08-03 2020-02-06 Pharmaxis Ltd. Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof
CN110938059A (zh) 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) * 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
AU2019351122A1 (en) * 2018-09-28 2021-05-20 Acucela Inc. Inhibitors of VAP-1
AU2019351124A1 (en) 2018-09-28 2021-05-20 Acucela Inc. Inhibitors of VAP-1
EP3870162A4 (en) * 2018-10-24 2022-08-24 Metacrine, Inc. SSAO INHIBITORS AND USES THEREOF
CN112955214B (zh) * 2018-10-29 2024-05-07 勃林格殷格翰国际有限公司 吡啶基磺酰胺衍生物、药物组合物及其用途
BR112021004635A2 (pt) 2018-10-29 2021-05-25 Boehringer Ingelheim International Gmbh derivados de piridinil sulfonamida, composições farmacêuticas e usos das mesmas
WO2020117987A1 (en) * 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions and methods for the treatment of liver disorders
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
TWI835945B (zh) * 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
WO2020125776A1 (zh) 2018-12-20 2020-06-25 山东丹红制药有限公司 式(iv)化合物的工艺路线、晶型及其制备方法
KR102711244B1 (ko) * 2019-01-11 2024-09-26 트랜스테라 사이언시즈 (난징), 인크. 할로-알릴아민 화합물 및 그의 용도
US12258317B2 (en) * 2019-05-20 2025-03-25 Sunshine Lake Pharma Co., Ltd. Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof
WO2021012014A1 (en) * 2019-07-25 2021-01-28 Pharmaxis Ltd. Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof
AU2020377093A1 (en) * 2019-10-29 2022-05-12 Eccogene Inc. SSAO inhibitors and use thereof
WO2021102774A1 (zh) * 2019-11-28 2021-06-03 广东东阳光药业有限公司 一种作为ssao/vap-1抑制剂的胺类衍生物及其用途
US20230127498A1 (en) * 2020-03-25 2023-04-27 Terns, Inc. Treatment of respiratory disorders
CN111654920B (zh) * 2020-06-02 2022-03-11 重庆邮电大学 一种分布式能效子载波功率分配方法
JP7665122B2 (ja) * 2020-06-26 2025-04-21 シンタラ リミテッド ハロアリルアミン系二重アミンオキシダーゼ阻害剤
KR20230058112A (ko) 2020-08-25 2023-05-02 일라이 릴리 앤드 캄파니 Ssao 억제제의 다형체
CN114621243B (zh) * 2020-12-14 2024-03-01 上海拓界生物医药科技有限公司 一种磺酰胺类衍生物及其用途
CN114621189B (zh) * 2020-12-14 2024-01-02 上海拓界生物医药科技有限公司 一种内酰胺类衍生物及其用途
CN114621190B (zh) * 2020-12-14 2023-12-05 上海拓界生物医药科技有限公司 一种烯丙基胺类衍生物及其用途
AU2023331414A1 (en) * 2022-08-29 2025-03-27 Syntara Limited Novel selective inhibitors of lysyl oxidases
WO2024240633A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
WO2025107036A1 (en) * 2023-11-23 2025-05-30 Syntara Limited Dual inhibitors of amine oxidases and peroxidases, and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4454158A (en) 1981-06-01 1984-06-12 Merrell Toraude Et Compagnie Allyl amine MAO inhibitors
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ZA855101B (en) * 1984-07-13 1986-05-28 Merrell Dow Pharma Fluoroallylaine derivatives
US4699928A (en) 1984-07-13 1987-10-13 Merrell Dow Pharmaceuticals Inc. Fluoroallylamine derivatives
US4650907A (en) 1985-12-05 1987-03-17 Merrell Dow Pharmaceuticals Inc. Nonaromatic fluoroallylamine MAO inhibitors
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
KR100353304B1 (ko) 1996-10-01 2002-09-30 에스알아이 인터내셔널 맛이 차폐된 마이크로캡슐 조성물 및 이것의 제조 방법
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
JP4395200B2 (ja) 1997-10-28 2010-01-06 バンドー化学株式会社 皮膚貼付薬シート及びそのための基材シートの製造方法
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
WO2004018997A2 (en) 2002-08-20 2004-03-04 Neurogenetics, Inc. Methods and compositions for modulating amyloid beta
JP2007523955A (ja) 2004-02-25 2007-08-23 ラ ホヤ ファーマシューティカル カンパニー 疾患の治療のためのアミンおよびアミド
CN1921841A (zh) * 2004-02-25 2007-02-28 拉卓拉药物公司 用于治疗疾病的胺和酰胺类化合物
US9161922B2 (en) 2005-07-01 2015-10-20 Case Western Reserve University Amine oxidase inhibitors
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
MX2009000715A (es) 2006-07-19 2009-07-22 Osurf Ohio State University Re Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos.
CN103120690A (zh) 2007-10-19 2013-05-29 株式会社·R-技术上野 用于治疗白内障的药物组合物
WO2009061830A1 (en) 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
CN101917845A (zh) * 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
UA112154C2 (uk) 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
MX377635B (es) * 2012-05-02 2025-03-11 Boehringer Ingelheim Int Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos

Also Published As

Publication number Publication date
EP2844637B1 (en) 2018-03-28
JP6182595B2 (ja) 2017-08-16
US20150158813A1 (en) 2015-06-11
CA2871793C (en) 2020-09-15
PL2844637T3 (pl) 2018-09-28
US9302986B2 (en) 2016-04-05
TR201807453T4 (tr) 2018-06-21
WO2013163675A1 (en) 2013-11-07
KR102089935B1 (ko) 2020-03-18
DK2844637T5 (en) 2018-08-13
BR112014027406A2 (pt) 2017-06-27
HK1203477A1 (en) 2015-10-30
AU2013203655B2 (en) 2017-02-02
CN107266332B (zh) 2020-07-24
US9815782B2 (en) 2017-11-14
JP2020019810A (ja) 2020-02-06
MX2014013294A (es) 2015-05-08
AU2013203655A1 (en) 2013-11-21
SG11201406948PA (en) 2014-11-27
ME03063B (me) 2019-01-20
EP2844637A1 (en) 2015-03-11
AU2013255103B2 (en) 2016-09-29
PT2844637T (pt) 2018-04-17
AU2013255103A1 (en) 2014-11-06
EP3438087A1 (en) 2019-02-06
US20160244406A1 (en) 2016-08-25
KR20200030126A (ko) 2020-03-19
US20190071396A1 (en) 2019-03-07
CY1120334T1 (el) 2019-07-10
DK2844637T3 (en) 2018-04-23
SI2844637T1 (en) 2018-07-31
CA3086105A1 (en) 2013-11-07
SG10201707020TA (en) 2017-10-30
JP2017132767A (ja) 2017-08-03
HK1245237A1 (zh) 2018-08-24
US10160723B2 (en) 2018-12-25
JP6602802B2 (ja) 2019-11-06
US20180086698A1 (en) 2018-03-29
NO2842608T3 (cg-RX-API-DMAC7.html) 2018-07-21
CN104520268B (zh) 2017-05-24
CN104520268A (zh) 2015-04-15
CN107266332A (zh) 2017-10-20
LT2844637T (lt) 2018-05-10
HRP20180953T1 (hr) 2018-07-27
HUE038437T2 (hu) 2018-10-29
MX360634B (es) 2018-11-12
JP2015521167A (ja) 2015-07-27
KR20150014926A (ko) 2015-02-09
RS57086B1 (sr) 2018-06-29
BR112014027406B1 (pt) 2020-09-24
MX377635B (es) 2025-03-11
CA2871793A1 (en) 2013-11-07
EP2844637A4 (en) 2015-12-09

Similar Documents

Publication Publication Date Title
ES2668300T3 (es) Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos
EP3458448B1 (en) Fasn inhibitors for use in treating non-alcoholic steatohepatitis
ES3002189T3 (en) Para-hydroquinone derivatives as vegf, tnf and/or il inhibitors for the treatment of neuroinflammatory diseases
EP3472133A1 (en) Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins
WO2020213693A1 (ja) リポ酸プロドラッグ
HK1245237B (zh) Ssao的取代的3-卤代烯丙基胺抑制剂及其用途
HK1203477B (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
CN111138422B (zh) 一种用于防治红斑狼疮的药物及其制备方法
CA2372731A1 (en) Oligo-amine/oligo-carboxy sulfonamides
CN118666903A (zh) 一种具有抗病毒活性的化合物
WO2021241582A1 (ja) 老視の治療または予防に有用な含硫黄化合物
US20180258121A1 (en) Highly efficient nrf2 activators-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation